The company expects Q3 revenues of $117.7 million-$118.5 million (vs. consensus of $111.78 million).

By segment, revenue from the Surgical segment ranges is $103.3 million-$103.9 million, and the EOS segment is $14.3 million-$14.5 million. 

The company witnessed strong ATEC lateral adoption growth, driving total revenue and surgical revenue growth of 31% to 32%.

FY23 Outlook: ATEC raised revenue outlook to $472 million (vs. consensus of $462.69 million) from $462 million.

The company will report Q3 2023 results on November 6, 2023. 

Price Action: ATEC shares are trading higher by 1.96% at $11.43 on the last check Monday.